Interviews were conducted in regional language 2 4 months after the declaration of treatment outcome by the field investigators in the presence of a field supervisor.
After the declaration of treatment outcome of the cohort, for every defaulted patient (case), one patient from completed group (control) was matched by age group, gender and treatment center.
There is no consensus about continued drug treatment after declaration of treatment failure with no further options of cure.
Informed consent was obtained from the patients' guardians according to the Declaration of Helsinki; treatment and genetic study protocols were approved by the Institutional Review Boards of the participating institutions.
After receiving approval from the Ethics Committee of Sohag Faculty of Medicine and written consent from the patient according to the Declaration of Helsinki, treatment using 3BP was planned at safe, low therapeutic doses, based on previous reports and published studies of 3BP [16], [18], [24], [25], [25].
For this, the auxiliary data (related to patients) used in the model were as follows: age, time to death, treatment arm, declaration of severe side effect, time to treatment failure and previous scores.
FOA or Invisalign® for at least six months; Modified sulcus bleeding index (SBI) ≤20%% [ 9] prior to orthodontic treatment; Approximal plaque index (API) ≤25%% [ 9] prior to orthodontic treatment; Declaration of consent.
The following patient inclusion criteria were applied: FOA or Invisalign® for at least six months; Modified sulcus bleeding index (SBI) ≤20%% [ 9 ] prior to orthodontic treatment; Approximal plaque index (API) ≤25%% [ 9 ] prior to orthodontic treatment; Declaration of consent.
The research adhered to the tenets of the Declaration of Helsinki in the treatment of human subjects.
Written informed consent from the parents or guardians of the study participants were obtained in accordance to the Declaration of Helsinki before initiation of treatments, and the protocols were approved by the ethics committee of Institute of Hematology and Blood Diseases Hospital.
Informed consent was obtained from the patients' guardians according to the Declaration of Helsinki and the protocols of treatment, and the genetic study were approved by the institutional review boards of the participating institutes.
